Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.70 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 9/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.54 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.51 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.51 |
| ▸ | DUSP26 | Q9BV47 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355912 | 1.00 | PIK3CD (0.70) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL189609 | 0.90 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL188557 | 0.90 | PIK3CD (0.84) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL2303217 | 0.89 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL189335 | 0.87 | PIK3CD (0.76) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL188977 | 0.84 | PIK3CG (0.87) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL2301525 | 0.84 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL188780 | 0.84 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL4562410 | 0.83 | PIK3CD (0.83) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT | |
| SCHEMBL2305856 | 0.82 | PIK3CD (0.76) | PIK3CDPIK3CAPIK3CGPIK3CBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | claimed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | claimed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | claimed |
| JP-2009506015-A | — | — | 2009-02-12 | — | — | JP | claimed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | claimed |
| EP-2365810-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2351745-A1 | Pyrazine derivatives and use as PI3K inhibitors | Merck Serono S.A. (CH) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | PIK3CD 74/4885PIK3CA 70/4885PIK3CG 110/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | PIK3CD 2/4885PIK3CA 3/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.